Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains

Prospective Study for Clinical Validation of the Molecular-Based GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains in Vaginal/Rectal Swab Specimens, After Lim Broth Enrichment, From Pregnant Women

The primary purpose of this clinical investigation is to verify the performance of the GenePOC GBS Assay on the GenePOC Instrument. This will be achieved by comparing the Assay to the a Culture, a conventional method for detection of Streptococcus agalactiae in vaginal/rectal swab specimens from antepartum women.

Study Overview

• Status: Completed
• Conditions: Streptococcus Agalactiae Infection
• Intervention / Treatment: Device: Comparison between GenePOC PCR and Reference Method

Detailed Description

The GenePOC GBS Test performed on the GenePOC System is a qualitative in vitro diagnostic (IVD) test designed to detect Group B Streptococcus (GBS) DNA from vaginal/rectal swabs from antepartum women following enrichment in Lim broth for 18-24 hours.

The GenePOC GBS Test utilizes automated sample preparation and real-time polymerase chain reaction (PCR) to detect a cfb gene sequence specific to the Streptococcus agalactiae genome. The GenePOC GBS Test is indicated for the identification of antepartum GBS colonization and does not provide susceptibility results. Culture isolates are needed for performing susceptibility testing as recommended for penicillin-allergic women.

The GenePOC GBS is an IVD system is comprised of the GenePOC Diagnostics System and the GenePOC Group B Step [GBS] Test, the components of which are:

1. Instrument
2. GBS disposable microfluidic cartridges (PIE) (described in this document as PIEs because of the shape of the cartridge)
3. GBS Sample Buffer Tube (SBT)
4. Sample Transfer Device (STD).

The GenePOC Instrument is fully automated and integrates sample lysis, dilution, amplification and detection of the target sequence in complex samples using real-time Polymerase chain reaction (rtPCR). User intervention is only required for discharging the patient sample into the SBT (sample Buffer Tube), transferring the sample into the PIE and for loading/unloading the PIEs into the instrument. The GenePOC instrument consists of a rotor to spin the PIEs, temperature control, fluorescence detection, a tactile user-friendly interface, two barcode readers, and integrated firmware and software to deliver results to the user. The PIE is a closed system that prevents the risk of contamination.

Lim Broth is used for the selective enrichment of group B streptococci (Streptococcus agalactiae). An aliquot of the broth is mixed with GenePOC Sample Buffer Tube Reagent (SBT), after which a sample is transferred to the GenePOC GBS PIE. The GenePOC GBS PIE is then automatically processed by the GenePOC Instrument.

On completion of a run, the user removes the processed PIEs from the instrument and discards them according to local biological waste management procedures.

One GenePOC instrument per site will be allocated. The purpose of the clinical investigation is to enroll sufficient specimens from four (4) Clinical Centers to obtain a total of 150 specimens positive for GBS based on the Reference Method final result.

Subject Informed consent is not required for this clinical trial as the testing will be performed on excess de-identified specimens only.

• Study Type: Interventional
• Enrollment (Actual): 771
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Québec, Canada, G1V 4G2
    • CHU de Québec - Université Laval
  • Ontario
    • Toronto, Ontario, Canada, M5G 1X5
      • Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex
• United States
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Detroit Medical Center University Laboratories
  • New Mexico
    • Albuquerque, New Mexico, United States, 87102
      • Tricore Laboratory University of New Mexico

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Antepartum pregnant women
• 18 years old and more
• Being at a gestation period of 35 to 37 weeks.
• Vaginal/rectal swab specimen

• Transport and storage times, and conditions (e.g. room temperature and/or refrigerated) within the labeled indications.

  • Fresh specimens available to be tested with the GenePOC GBS System within 96 hours (4 days) of collection if kept at 2-25°C
  • Fresh specimens must be tested with the Reference Method within 96 hours (4 days) of collection if kept at 2-25°C
• The GenePOC GBS System and the Reference Method will be performed according to the GenePOC GBS Investigation Documents.
• Materials use within their expiration date

Exclusion Criteria:

• Non pregnant women
• Less than 18 years old
• Gestation not between 35-37 weeks
• Transport and storage times and conditions that exceed these Study Protocol requirements
• The GenePOC GBS System and the Reference Method not performed according to the GenePOC GBS Investigation Documents
• Materials used beyond their expiration date
• Specimens without all test results required by this Study Protocol. Specimens that are inadvertently entered into the study that do not meet the specimen inclusion criteria will be made non-compliant.
• The GenePOC GBS System and the Reference Method not performed according to the GenePOC GBS Investigation Documents.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: DIAGNOSTIC
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Accuracy Testing; Comparison between GenePOC PCR and Reference Method	Device: Comparison between GenePOC PCR and Reference Method; Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Performance Characteristics	To establish the performance characteristics of the GenePOC GBS System for its use in determining the presence of GBS in vaginal/rectal swab, after Lim Broth enrichment, specimens from antepartum pregnant women. Sensitivity and specificity will be established in comparison to the Reference Method. Sensitivity performance results from the comparison of specimens being reported as positive by both method against the total number of specimen reported as positive on the Reference Method only. Sensitivity is reported as a percentage (i.e. concondant positives / concordant positive + discordant positive ([False Negative]). Specificity performance results from the comparison of specimens being reported as negative by both method against the total number of specimen reported as negative on the Reference Method only. Specificity is reported as a percentage (i.e. concondant negatives / concordant negatives + discordant negatives ([False Positive]).	At the time of the results with Reference Method is confirmed, up to 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Positive and Negative Predictive Values	To estimate the Positive and Negative Predictive Values (PPV and NPV) of the GenePOC GBS System. PPV results from the comparison of specimens being reported as positive by both method against the total number of specimen reported as positive on the Investigational test only. PPV is reported as a percentage (i.e. concondant positives / concordant positive + discordant positive ([False Positive]). NPV results from the comparison of specimens being reported as negative by both method against the total number of specimen reported as negative on the Investigational test only. NPV is reported as a percentage (i.e. concondant negatives / concordant negatives + discordant negatives ([False Negative]).	At the time of the results with Reference Method is confirmed, up to 6 months
Unresolved Sample Results	To estimate the rate of unresolved results for the GenePOC GBS System due to Sample Processing control failure (unresolved sample results).	At the time of the results with Reference Method is confirmed, up to 6 months
Indeterminate Sample Results	To estimate the rate of indeterminate results for the GenePOC GBS Test due to an Instrument failure (indeterminate sample results).	At the time of the results with Reference Method is confirmed, up to 6 months

Collaborators and Investigators

• Sponsor: Meridian Bioscience, Inc.

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 10, 2016
• Primary Completion (ACTUAL): February 7, 2017
• Study Completion (ACTUAL): February 7, 2017

Study Registration Dates

• First Submitted: March 15, 2016
• First Submitted That Met QC Criteria: March 18, 2016
• First Posted (ESTIMATE): March 24, 2016

Study Record Updates

• Last Update Posted (ACTUAL): May 3, 2021
• Last Update Submitted That Met QC Criteria: April 29, 2021
• Last Verified: November 1, 2018

More Information

Terms related to this study

• Keywords: Polymerase Chain Reaction (PCR); GBS; Streptococcus agalactiae; Antepartum women
• Additional Relevant MeSH Terms: Infections; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Streptococcal Infections
• Other Study ID Numbers: GenePOC-GBS_clinical-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated device product: Yes